Evidence map›Paper›PMID 42449379›Full record

Observational studyAlzheimer's research & therapy2026

Disruption of temporo-parietal network in Alzheimer's disease and its association with memory impairment.

Yanin Suksangkharn, Björn Hendrik Schott, Peter Zeidman, Niklas Vockert, René Lattmann, Hartmut Schütze, Renat Yakupov, Oliver Peters, Julian Hellmann-Regen, Lukas Preis and 28 more

Abstract readMulticenter StudyObservational Study
In one paragraph

Observational study in Alzheimer's research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

38 authors.

Yanin SuksangkharnGerman Center for Neurodegenerative Diseases (DZNE), Magdeburg, 39120, Germany. yanin.suksangkharn@dzne.de.
Björn Hendrik SchottGerman Center for Neurodegenerative Diseases (DZNE), Göttingen, 37075, Germany.
Peter ZeidmanFunctional Imaging Laboratory, UCL Department of Imaging Neuroscience, 12 Queen Square, London, WC1N 3AR, UK.
Niklas VockertGerman Center for Neurodegenerative Diseases (DZNE), Magdeburg, 39120, Germany.
René LattmannGerman Center for Neurodegenerative Diseases (DZNE), Magdeburg, 39120, Germany.
Hartmut SchützeGerman Center for Neurodegenerative Diseases (DZNE), Magdeburg, 39120, Germany.
Renat YakupovGerman Center for Neurodegenerative Diseases (DZNE), Magdeburg, 39120, Germany.
Oliver PetersGerman Center for Neurodegenerative Diseases (DZNE), Berlin, 10117, Germany.
Julian Hellmann-RegenGerman Center for Neurodegenerative Diseases (DZNE), Berlin, 10117, Germany.
Lukas PreisDepartment of Psychiatry and Neurosciences, Charité Universitätsmedizin Berlin, Hindenburgdamm 30, Berlin, 12203, Germany.
Ersin ErsözlüGerman Center for Neurodegenerative Diseases (DZNE), Berlin, 10117, Germany.
Josef PrillerGerman Center for Neurodegenerative Diseases (DZNE), Berlin, 10117, Germany.
Eike Jakob SpruthGerman Center for Neurodegenerative Diseases (DZNE), Berlin, 10117, Germany.
Janna BeckmannGerman Center for Neurodegenerative Diseases (DZNE), Berlin, 10117, Germany.
Anja SchneiderGerman Center for Neurodegenerative Diseases (DZNE), Bonn/Cologne, Venusberg-Campus 1, Bonn, 53127, Germany.
Klaus FliessbachGerman Center for Neurodegenerative Diseases (DZNE), Bonn/Cologne, Venusberg-Campus 1, Bonn, 53127, Germany.
Jens WiltfangGerman Center for Neurodegenerative Diseases (DZNE), Göttingen, 37075, Germany.
Claudia BartelsDepartment of Psychiatry and Psychotherapy, University Medical Center Goettingen, University of Goettingen, Von-Siebold-Str. 5, Goettingen, 37075, Germany.
Ayda RostamzadehDepartment of Psychiatry, Medical Faculty, University of Cologne, Kerpener Strasse 62, Cologne, 50924, Germany.
Wenzel GlanzGerman Center for Neurodegenerative Diseases (DZNE), Magdeburg, 39120, Germany.
Enise I IncesoyGerman Center for Neurodegenerative Diseases (DZNE), Magdeburg, 39120, Germany.
Stefan TeipelGerman Center for Neurodegenerative Diseases (DZNE), Rostock, Germany.
Ingo KilimannGerman Center for Neurodegenerative Diseases (DZNE), Rostock, Germany.
Doreen GoerssGerman Center for Neurodegenerative Diseases (DZNE), Rostock, Germany.
Christoph LaskeGerman Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany.
Annika SpottkeGerman Center for Neurodegenerative Diseases (DZNE), Bonn/Cologne, Venusberg-Campus 1, Bonn, 53127, Germany.
Marie KronmüllerGerman Center for Neurodegenerative Diseases (DZNE), Bonn/Cologne, Venusberg-Campus 1, Bonn, 53127, Germany.
Frederic BrosseronGerman Center for Neurodegenerative Diseases (DZNE), Bonn/Cologne, Venusberg-Campus 1, Bonn, 53127, Germany.
Falk LüsebrinkGerman Center for Neurodegenerative Diseases (DZNE), Magdeburg, 39120, Germany.
Matthias SchmidGerman Center for Neurodegenerative Diseases (DZNE), Bonn/Cologne, Venusberg-Campus 1, Bonn, 53127, Germany.
Luca KleineidamGerman Center for Neurodegenerative Diseases (DZNE), Bonn/Cologne, Venusberg-Campus 1, Bonn, 53127, Germany.
Melina StarkGerman Center for Neurodegenerative Diseases (DZNE), Bonn/Cologne, Venusberg-Campus 1, Bonn, 53127, Germany.
Stefan HetzerBerlin Center for Advanced Neuroimaging, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Peter DechentMR-Research in Neurosciences, Department of Cognitive Neurology, University Medical Center Goettingen, Georg-August-University Goettingen, Goettingen, Germany.
Frank JessenGerman Center for Neurodegenerative Diseases (DZNE), Bonn/Cologne, Venusberg-Campus 1, Bonn, 53127, Germany.
Anne MaassGerman Center for Neurodegenerative Diseases (DZNE), Magdeburg, 39120, Germany.
Emrah Düzel *German Center for Neurodegenerative Diseases (DZNE), Magdeburg, 39120, Germany.
Gabriel Ziegler *German Center for Neurodegenerative Diseases (DZNE), Magdeburg, 39120, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease (AD) is characterised by the accumulation of β-amyloid (Aβ) and tau proteins, resulting in neurodegeneration and cognitive decline. Although Aβ and tau disrupt synaptic function, the association linking these molecular pathologies to network-level dysfunction and memory impairment remains poorly understood. Here, we investigated the effects of Aβ and tau pathology (CSF Aβ42/40 ratio and tau phosphorylated at position 181, p-tau-181, respectively) on effective connectivity related to memory encoding, which may provide a link between synaptic pathology and cognitive outcomes. Functional magnetic resonance imaging (fMRI) during visual memory encoding was acquired from 205 participants in the multicentric DZNE Longitudinal Cognitive Impairment and Dementia Study (DELCODE) across the AD spectrum. Effective connectivity was assessed using Dynamic Causal Modelling (DCM) of task-fMRI data, focusing on the parahippocampal place area (PPA), hippocampus (HC), and precuneus (PCU)-regions central to memory encoding. Disruptions in connectivity between temporal and parietal lobes were associated with both memory impairment and indices of AD pathology. Specifically, reduced positive effective connectivity from the PCU to the PPA and from the HC to the PCU were linked to higher p-tau-181 levels, with an amplification effect observed in the presence of amyloid accumulation for the latter connectivity. The disruption from the PCU to the PPA was found to be associated with decreased memory performance. Together, these findings indicate that temporo-parietal connectivity is associated with both AD molecular pathology and, for a subset of connections, with memory performance.

Indexed as

Alzheimer DiseaseMemory DisordersParietal LobeTemporal LobeAgedAged, 80 and overAmyloid beta-PeptidesFemaleHumansLongitudinal StudiesMagnetic Resonance ImagingMaleNeural PathwaysNeuropsychological TestsPeptide Fragmentstau ProteinsAmyloid beta-Peptidesamyloid beta-protein (1-40)amyloid beta-protein (1-42)Peptide Fragmentstau ProteinsAlzheimer's diseaseBeta-amyloidMemory impairmentNeurodegenerationSynaptic aberrationTau

Identifiers

PMID42449379
PMCPMC13374064

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.